Related Experiment Video
Updated: Jul 6, 2026
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Current and future treatment modalities for Clostridium difficile-associated disease
1West Allis Memorial Hospital, 8901 West Lincoln Avenue, West Allis, WI 53227, USA. jennifer.halsey@aurora.org
Summary
Clostridium difficile-associated disease (CDAD) treatment involves stopping the offending antibiotic and using targeted therapies like metronidazole or vancomycin. Future research focuses on improved diagnostics and vaccine development for this significant healthcare concern.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Gastroenterology
Background:
- Clostridium difficile is a leading cause of antibiotic-associated diarrhea in healthcare settings.
- Infections can progress to severe conditions like pseudomembranous colitis.
- Recent outbreaks highlight increased virulence and treatment challenges.
Purpose of the Study:
- To review current and future treatment strategies for Clostridium difficile-associated disease (CDAD).
Main Methods:
- Review of existing literature on CDAD treatments.
- Analysis of therapeutic options including antibiotics, probiotics, and IVIG.
- Exploration of potential vaccine targets and diagnostic advancements.
Main Results:
- First-line treatment for CDAD is metronidazole, with vancomycin used for severe or resistant cases.
- Alternative therapies include intracolonic vancomycin, nitazoxanide, rifaximin, IVIG, and probiotics.
- Vaccine development is exploring targets such as C. difficile toxins and surface proteins.
Conclusions:
- CDAD poses a significant threat to healthcare systems.
- Enhanced diagnostic tests are crucial for timely intervention.
- Continued research into novel treatments and vaccines is essential for effective CDAD management.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...